AROA secures 2027 US reimbursement certainty for Symphony products

Reimbursement certainty remains an important factor in the adoption of advanced wound care products across the United States, where payment arrangements influence how healthcare providers access and use treatments.

A recent announcement by Aroa Biosurgery (ASX:ARX) highlighted this point, with the company reporting that the US Centers for Medicare & Medicaid Services (CMS) will maintain the existing outpatient payment rate for its AROA ECM™ sheet products in 2027, and extend the same rate to non-sheet products in physician offices.

The final CMS reimbursement rules, published on 4 November 2026, retain a payment rate of US$127.14 per square centimetre of wound area treated. The arrangements provide greater certainty for Symphony™ as Aroa Biosurgery continues to pursue opportunities in outpatient healthcare settings.

Aroa Biosurgery Founder and CEO Brian Ward said the company welcomed the outcome following significant changes to outpatient reimbursement.

“We welcome the greater payment certainty these rules provide for healthcare providers and hospitals following significant change in outpatient reimbursement. Symphony is well positioned in this environment, supported by compelling clinical evidence and responsible pricing.”

Maintains Symphony’s outpatient payment rate

From 1 January 2027, Symphony will continue to receive a payment rate of US$127.14 per square centimetre of wound area treated across hospital outpatient departments, ambulatory surgical centres and physician offices.

The decision is consistent with the proposed reimbursement framework outlined in Aroa Biosurgery’s earlier announcement dated 14 July 2026.

The continued payment arrangement gives healthcare providers greater certainty around reimbursement when using Symphony in outpatient settings. Aroa Biosurgery believes the product’s pricing, supported by its recently published randomised controlled trial, positions it for adoption in this market.

The company said recent changes to outpatient reimbursement support the opportunity for Symphony, while its primary focus remains Myriad in the hospital inpatient setting.

Extends payment arrangements to non-sheet products

The final rules also introduce a standard national payment rate for non-sheet products used in physician offices.

From 1 January 2027, these products will receive US$127.14 per square centimetre, with payment calculated according to the wound area treated.

This creates a new opportunity for morcellised versions of AROA ECM™, extending the standardised payment framework beyond sheet products in physician office settings.

The change provides another potential route for Aroa Biosurgery’s technology in the US outpatient market, alongside the continued reimbursement arrangements for Symphony.

Keeps Myriad reimbursement unchanged

Aroa Biosurgery said its primary commercial focus remains Myriad in the hospital inpatient setting, where reimbursement is already well established and is unaffected by the latest outpatient changes.

The company develops products for complex wound healing and soft tissue reconstruction using its proprietary AROA ECM™ technology platform, an extracellular matrix bioscaffold derived from ovine (sheep) forestomach.

More than 7.5 million AROA devices have been used globally across a range of procedures. The company is headquartered in Auckland, New Zealand, and distributes its products in the US through its direct sales force and partner TELABio, Inc.

The 2027 CMS rules provide continuity for Symphony’s existing outpatient payment rate and establish a standard rate for non-sheet products in physician offices, effective from the start of the new calendar year.